{"pmid":32312781,"title":"Nafamostat mesylate blocks activation of SARS-CoV-2: New treatment option for COVID-19.","text":["Nafamostat mesylate blocks activation of SARS-CoV-2: New treatment option for COVID-19.","The currently unfolding coronavirus pandemic threatens health systems and economies worldwide.....","Antimicrob Agents Chemother","Hoffmann, Markus","Schroeder, Simon","Kleine-Weber, Hannah","Muller, Marcel A","Drosten, Christian","Pohlmann, Stefan","32312781"],"abstract":["The currently unfolding coronavirus pandemic threatens health systems and economies worldwide....."],"journal":"Antimicrob Agents Chemother","authors":["Hoffmann, Markus","Schroeder, Simon","Kleine-Weber, Hannah","Muller, Marcel A","Drosten, Christian","Pohlmann, Stefan"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32312781","week":"202017|Apr 20 - Apr 26","doi":"10.1128/AAC.00754-20","source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"locations":["Nafamostat"],"e_drugs":["nafamostat"],"_version_":1664714520032968704,"score":8.518259,"similar":[{"pmid":32302456,"title":"Potential of Heparin and Nafamostat Combination Therapy for COVID-19.","text":["Potential of Heparin and Nafamostat Combination Therapy for COVID-19.","Tang et al. recently reported that (Journal of Thrombosis and Haemostasis), in COVID-19 infections caused by the novel coronavirus (SARS-CoV-2), heparin anticoagulant therapy lowers the mortality rate in patients who present with markedly elevated concentrations of D-dimer 1). In other words, abnormal coagulation may influence the prognosis of COVID-19. This is extremely interesting. The article did not describe to what extent heparin improves the abnormal coagulation and further studies by this group are anticipated. The authors reported in that article 1) and a previous article 2) that the abnormal coagulation seen in non-survivors of COVID-19 clearly differs from the abnormal coagulation typically seen in other severe infectious diseases.","J Thromb Haemost","Asakura, Hidesaku","Ogawa, Haruhiko","32302456"],"abstract":["Tang et al. recently reported that (Journal of Thrombosis and Haemostasis), in COVID-19 infections caused by the novel coronavirus (SARS-CoV-2), heparin anticoagulant therapy lowers the mortality rate in patients who present with markedly elevated concentrations of D-dimer 1). In other words, abnormal coagulation may influence the prognosis of COVID-19. This is extremely interesting. The article did not describe to what extent heparin improves the abnormal coagulation and further studies by this group are anticipated. The authors reported in that article 1) and a previous article 2) that the abnormal coagulation seen in non-survivors of COVID-19 clearly differs from the abnormal coagulation typically seen in other severe infectious diseases."],"journal":"J Thromb Haemost","authors":["Asakura, Hidesaku","Ogawa, Haruhiko"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32302456","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jth.14858","source":"PubMed","topics":["Treatment"],"weight":1,"locations":["D-dimer","Heparin"],"e_drugs":["Heparin","nafamostat"],"_version_":1664635401218818048,"score":82.008736},{"pmid":32300370,"pmcid":"PMC7148425","title":"Can an effective SARS-CoV-2 vaccine be developed for the older population?","text":["Can an effective SARS-CoV-2 vaccine be developed for the older population?","The emergence of SARS-CoV-2 and its inordinately rapid spread is posing severe challenges to the wellbeing of millions of people worldwide, health care systems and the global economy. While many younger people experience no or mild symptoms on infection, older adults are highly susceptible to life-threatening respiratory and systemic conditions which demand a full understanding and leveraging of knowledge of the differences between immunity in young and old people. Consequently, we welcome papers addressing any issues relevant to immunity and ageing in the context of SARS-CoV-2, and will endeavour to fast-track peer-review. We aim to provide a platform exclusively for discussions of individual and age differences in susceptibility and immune responses to COVID caused by SARS-CoV-2 infection and how to prevent or reduce severity of disease in older adults.","Immun Ageing","Pawelec, Graham","Weng, Nan-Ping","32300370"],"abstract":["The emergence of SARS-CoV-2 and its inordinately rapid spread is posing severe challenges to the wellbeing of millions of people worldwide, health care systems and the global economy. While many younger people experience no or mild symptoms on infection, older adults are highly susceptible to life-threatening respiratory and systemic conditions which demand a full understanding and leveraging of knowledge of the differences between immunity in young and old people. Consequently, we welcome papers addressing any issues relevant to immunity and ageing in the context of SARS-CoV-2, and will endeavour to fast-track peer-review. We aim to provide a platform exclusively for discussions of individual and age differences in susceptibility and immune responses to COVID caused by SARS-CoV-2 infection and how to prevent or reduce severity of disease in older adults."],"journal":"Immun Ageing","authors":["Pawelec, Graham","Weng, Nan-Ping"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32300370","week":"202016|Apr 13 - Apr 19","doi":"10.1186/s12979-020-00180-2","keywords":["covid","immunosenescence","sars-cov-2","severe acute respiratory syndrome","vaccination"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664635401354084353,"score":79.54989},{"pmid":32142651,"pmcid":"PMC7102627","title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.","text":["SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.","The recent emergence of the novel, pathogenic SARS-coronavirus 2 (SARS-CoV-2) in China and its rapid national and international spread pose a global health emergency. Cell entry of coronaviruses depends on binding of the viral spike (S) proteins to cellular receptors and on S protein priming by host cell proteases. Unravelling which cellular factors are used by SARS-CoV-2 for entry might provide insights into viral transmission and reveal therapeutic targets. Here, we demonstrate that SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming. A TMPRSS2 inhibitor approved for clinical use blocked entry and might constitute a treatment option. Finally, we show that the sera from convalescent SARS patients cross-neutralized SARS-2-S-driven entry. Our results reveal important commonalities between SARS-CoV-2 and SARS-CoV infection and identify a potential target for antiviral intervention.","Cell","Hoffmann, Markus","Kleine-Weber, Hannah","Schroeder, Simon","Kruger, Nadine","Herrler, Tanja","Erichsen, Sandra","Schiergens, Tobias S","Herrler, Georg","Wu, Nai-Huei","Nitsche, Andreas","Muller, Marcel A","Drosten, Christian","Pohlmann, Stefan","32142651"],"abstract":["The recent emergence of the novel, pathogenic SARS-coronavirus 2 (SARS-CoV-2) in China and its rapid national and international spread pose a global health emergency. Cell entry of coronaviruses depends on binding of the viral spike (S) proteins to cellular receptors and on S protein priming by host cell proteases. Unravelling which cellular factors are used by SARS-CoV-2 for entry might provide insights into viral transmission and reveal therapeutic targets. Here, we demonstrate that SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming. A TMPRSS2 inhibitor approved for clinical use blocked entry and might constitute a treatment option. Finally, we show that the sera from convalescent SARS patients cross-neutralized SARS-2-S-driven entry. Our results reveal important commonalities between SARS-CoV-2 and SARS-CoV infection and identify a potential target for antiviral intervention."],"journal":"Cell","authors":["Hoffmann, Markus","Kleine-Weber, Hannah","Schroeder, Simon","Kruger, Nadine","Herrler, Tanja","Erichsen, Sandra","Schiergens, Tobias S","Herrler, Georg","Wu, Nai-Huei","Nitsche, Andreas","Muller, Marcel A","Drosten, Christian","Pohlmann, Stefan"],"date":"2020-03-07T11:00:00Z","year":2020,"_id":"32142651","week":"202010|Mar 02 - Mar 08","doi":"10.1016/j.cell.2020.02.052","keywords":["ace2","covid-19","sars-cov-2","tmprss2","coronavirus","entry","neutralization","priming","spike"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Serine"],"_version_":1664640874920804356,"score":77.16181},{"pmid":32134278,"title":"Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19).","text":["Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19).","Last decade witnessed the outbreak of many life-threatening human pathogens including Nipah, Ebola, Chikungunya, Zika, Middle East respiratory syndrome coronavirus (MERS-CoV), Severe Acute respiratory syndrome coronavirus (SARS-CoV) and more recently novel coronavirus (2019-nCoV or SARS-CoV-2). The disease condition associated with novel coronavirus, referred to as Coronavirus disease (COVID-19). The emergence of novel coronavirus in 2019 in Wuhan, China marked the third highly pathogenic coronavirus infecting humans in the 21st century. The continuing emergence of coronaviruses at regular intervals poses a significant threat to human health and economy. Ironically, even after a decade of research on coronavirus, still there are no licensed vaccines or therapeutic agents to treat coronavirus infection which highlights an urgent need to develop effective vaccines or post-exposure prophylaxis to prevent future epidemics. Several clinical, genetic and epidemiological features of COVID-19 resemble SARS-CoV infection. Hence, the research advancements on SARS-CoV treatment might help scientific community in quick understanding of this virus pathogenesis and develop effective therapeutic/prophylactic agents to treat and prevent this infection. Monoclonal antibodies represent the major class of biotherapeutics for passive immunotherapy to fight against viral infection. The therapeutic potential of monoclonal antibodies has been well recognized in the treatment of many diseases. Here, we summarize the potential monoclonal antibody based therapeutic intervention for COVID-19 by considering the existing knowledge on the neutralizing monoclonal antibodies against similar coronaviruses SARS-CoV and MERS-CoV. Further research on COVID-19 pathogenesis could identify appropriate therapeutic targets to develop specific anti-virals against this newly emerging pathogen.","Asian Pac J Allergy Immunol","Shanmugaraj, Balamurugan","Siriwattananon, Konlavat","Wangkanont, Kittikhun","Phoolcharoen, Waranyoo","32134278"],"abstract":["Last decade witnessed the outbreak of many life-threatening human pathogens including Nipah, Ebola, Chikungunya, Zika, Middle East respiratory syndrome coronavirus (MERS-CoV), Severe Acute respiratory syndrome coronavirus (SARS-CoV) and more recently novel coronavirus (2019-nCoV or SARS-CoV-2). The disease condition associated with novel coronavirus, referred to as Coronavirus disease (COVID-19). The emergence of novel coronavirus in 2019 in Wuhan, China marked the third highly pathogenic coronavirus infecting humans in the 21st century. The continuing emergence of coronaviruses at regular intervals poses a significant threat to human health and economy. Ironically, even after a decade of research on coronavirus, still there are no licensed vaccines or therapeutic agents to treat coronavirus infection which highlights an urgent need to develop effective vaccines or post-exposure prophylaxis to prevent future epidemics. Several clinical, genetic and epidemiological features of COVID-19 resemble SARS-CoV infection. Hence, the research advancements on SARS-CoV treatment might help scientific community in quick understanding of this virus pathogenesis and develop effective therapeutic/prophylactic agents to treat and prevent this infection. Monoclonal antibodies represent the major class of biotherapeutics for passive immunotherapy to fight against viral infection. The therapeutic potential of monoclonal antibodies has been well recognized in the treatment of many diseases. Here, we summarize the potential monoclonal antibody based therapeutic intervention for COVID-19 by considering the existing knowledge on the neutralizing monoclonal antibodies against similar coronaviruses SARS-CoV and MERS-CoV. Further research on COVID-19 pathogenesis could identify appropriate therapeutic targets to develop specific anti-virals against this newly emerging pathogen."],"journal":"Asian Pac J Allergy Immunol","authors":["Shanmugaraj, Balamurugan","Siriwattananon, Konlavat","Wangkanont, Kittikhun","Phoolcharoen, Waranyoo"],"date":"2020-03-06T11:00:00Z","year":2020,"_id":"32134278","week":"202010|Mar 02 - Mar 08","doi":"10.12932/AP-200220-0773","source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"locations":["Chikungunya","Zika","Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664640874952261632,"score":72.97983},{"pmid":32313207,"title":"Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor.","text":["Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor.","Cell Mol Immunol","Chen, Xiangyu","Li, Ren","Pan, Zhiwei","Qian, Chunfang","Yang, Yang","You, Renrong","Zhao, Jing","Liu, Pinghuang","Gao, Leiqiong","Li, Zhirong","Huang, Qizhao","Xu, Lifan","Tang, Jianfang","Tian, Qin","Yao, Wei","Hu, Li","Yan, Xiaofeng","Zhou, Xinyuan","Wu, Yuzhang","Deng, Kai","Zhang, Zheng","Qian, Zhaohui","Chen, Yaokai","Ye, Lilin","32313207"],"journal":"Cell Mol Immunol","authors":["Chen, Xiangyu","Li, Ren","Pan, Zhiwei","Qian, Chunfang","Yang, Yang","You, Renrong","Zhao, Jing","Liu, Pinghuang","Gao, Leiqiong","Li, Zhirong","Huang, Qizhao","Xu, Lifan","Tang, Jianfang","Tian, Qin","Yao, Wei","Hu, Li","Yan, Xiaofeng","Zhou, Xinyuan","Wu, Yuzhang","Deng, Kai","Zhang, Zheng","Qian, Zhaohui","Chen, Yaokai","Ye, Lilin"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32313207","week":"202017|Apr 20 - Apr 26","doi":"10.1038/s41423-020-0426-7","source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1664714520195497984,"score":71.921455}]}